Inventiva Aktie

5,61 EUR +0,13 EUR +2,37 %

20.02.2026

BMN

5,53 EUR +1,59 EUR +40,23 %

20.02.2026

LSE

Inventiva jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,15 Mrd. EUR

Div. Rendite0,00%

WKNA2DLV9

ISINFR0013233012

SymbolIVEVF

Inventiva Aktien News

Sortieren:Datum Meistgelesen

25.07.24GlobeNewswireInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

19.07.24GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

18.07.24GlobeNewswireInventiva announces a €20.1 million issuance of royalty certificates

05.07.24GlobeNewswireInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

21.06.24GlobeNewswireDescription of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

21.06.24GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

30.05.24GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30.05.24GlobeNewswireCombined General Meeting of June 20, 2024 - Availability of the preparatory documents

22.05.24GlobeNewswireInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

21.05.24GlobeNewswireInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

16.05.24GlobeNewswireInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

13.05.24GlobeNewswireInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with

03.04.24GlobeNewswireInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

28.03.24GlobeNewswireInventiva announces the nomination of Andre Turenne as Director

27.03.24GlobeNewswireInventiva reports its 2023 full-year results

22.03.24GlobeNewswireInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

18.03.24GlobeNewswireInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

13.03.24GlobeNewswireInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

07.03.24GlobeNewswireInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

15.02.24GlobeNewswireInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

24.01.24GlobeNewswireHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

10.01.24GlobeNewswireInventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

20.12.23GlobeNewswireInventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

04.12.23GlobeNewswireInventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

21.11.23GlobeNewswireInventiva reports 2023 Third Quarter Financial Information¹

06.11.23GlobeNewswireInventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023

28.09.23GlobeNewswireInventiva reports its 2023 first-half financial results and provides a corporate update

20.09.23GlobeNewswireInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

31.08.23GlobeNewswireInventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certifica

27.07.23GlobeNewswireInventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

24.06.23GlobeNewswireInventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

13.06.23GlobeNewswireInventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

08.06.23GlobeNewswireInventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients

07.06.23GlobeNewswireInventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

26.05.23GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

25.05.23GlobeNewswireInventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

25.05.23GlobeNewswireDescription of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023

16.05.23GlobeNewswireInventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

04.05.23GlobeNewswireStatement of total voting rights and shares forming the company’s share capital as of April 17, 2023

04.05.23GlobeNewswireCombined General Meeting of May 25, 2023. Availability of the preparatory documents

Inventiva News

Inventiva News: auf dieser Seite finden Sie alle Inventiva News und Nachrichten zur Inventiva Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Inventiva News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Inventiva News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.